News Wire

The FDA has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications S.A.) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera, which received…
Far more people than previously thought can benefit from an emergency procedure for acute ischemic stroke, according to a 38-center clinical trial sponsored by the National Institutes of Health and led by researchers at the Stanford University School of Medicine. The improved outcomes were achieved…
The 340B Drug Pricing Program, a 25-year-old discount plan aimed at boosting resources for hospitals treating low-income patients, has not delivered on its promise to enhance care for the needy, according to research from Harvard Medical School and the NYU School of Medicine. The federal program was…
Solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline, according to a report published in The New England Journal of Medicine. Researchers have proposed that Alzheimer’s disease…
Federal authorities are cracking down on 15 companies that are making unproven claims about unapproved products’ ability to help treat opioid addiction and withdrawal. The FDA and the Federal Trade Commission (FTC) jointly posted warning letters to the marketers and distributors of 12 opioid cessation…
The FDA has approved a second indication for plecanatide (Trulance, Synergy Pharmaceuticals Inc.): the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Plecanatide was already approved for the treatment of adults with chronic idiopathic constipation (CIC). The 3-mg…
An independent analysis of pharmaceutical industry efforts to tackle drug resistance gives high marks to GlaxoSmithKline and Johnson & Johnson among the large research-based pharmaceutical companies, while Mylan leads the generic medicine manufacturers and Entasis leads in the biotechnology group. The…
Patients with hard-to-treat episodic migraine experienced marked improvement in the phase 3B LIBERTY study of erenumab (Aimovig, Amgen), according to new trial results. The study assessed the efficacy and safety of erenumab 140 mg in patients with episodic migraine who had experienced two to four previous…
For obese people with diabetes, doctors have increasingly been offering gastric bypass surgery as a way to lose weight and control blood glucose levels. Short-term results are often impressive, but questions have remained about the long-term benefits of such operations. Now, a large, international study…
Of the 30 U.S. children who have died from the flu so far this season, some 85% had not been vaccinated, said Centers for Disease Control and Prevention Director Brenda Fitzgerald, MD, who urged Americans to get flu shots amid one of the most severe flu seasons in years. “My message is, if you haven’t…
While e-cigarettes are not without health risks, they are likely to be far less harmful than conventional cigarettes, according to a congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine. The committee that conducted the study concluded that e-cigarettes…
RAND Health researchers who studied how much U.S. medical practices were using electronic health records (EHRs) found only about a quarter using them to their full potential, while 39% of the practices were underusing EHRs. The study was funded under the Agency for Healthcare Research and Quality (AHRQ)…
The FDA has sent a complete response letter to Braeburn Pharmaceuticals regarding its new drug application for CAM2038, an investigational buprenorphine weekly and monthly depot injection for the treatment of adults with opioid use disorder (OUD). The FDA has requested additional information in order…
ASP0113 (Astellas Pharma Inc./ Vical Incorporated), an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant recipients, did not significantly improve overall mortality and CMV end-organ disease through the first year following the transplant,…
Two phase 3 studies evaluating a fixed 110-mg subcutaneous dose of reslizumab (Cinqair, Teva Pharmaceutical Industries Ltd.) failed to meet their primary endpoints: reducing exacerbations in patients with uncontrolled asthma in one trial, and reducing oral corticosteroid doses in asthma patients dependent…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA